Today was the final day of SBS 2023 and although we are sad to say goodbye, we are thrilled at having spent an eventful four days with all of you.
Glynis R. Ablon, MD, led the 2023 Aesthetics Update. She was joined by a panel of experts including Shasa Hu, MD, Doris J. Day, MD, Z. Paul Lorenc, MD, and Susan H. Weinkle, MD, to examine the latest in aesthetic technologies, techniques, and treatments. Dr. Hu looked closely at Millennials, highlighting how this patient group is changing the landscape of aesthetic treatment. She shed light on how social media influences the Millennial patient as well as providing useful tips for utilizing social media in your aesthetic practice. Dr. Weinkle updated attendees on the latest techniques for facial rejuvenation, sharing her own treatment pearls for placement and technique.
The LIVE Patient Facial Injections immediately followed this session, bringing back Dr. Weinkle, Dr. Hu, Dr. Lorenc, and Dr. Day. Attendees had the opportunity to see up close and personal how these top aesthetic experts examined their patients’ facial features prior to any facial rejuvenation procedure. This session is a favorite each year as it allows attendees to view first-hand how the nation’s most renowned aesthetic experts go about treating their patients to obtain the most satisfactory outcome.
Day Four of SBS also featured our final specialty session, the Atopic Dermatitis (AD) Workshop, led by Peter A. Lio, MD. Key experts including Karan Lal, DO, MS, Andrew F. Alexis, MD, MPH, Leon H. Kircik, MD, Brett A. King, MD, PhD, and Christopher G. Bunick, MD, PhD, took to the stage to review the various aspects of this skin condition. Dr. Lal kicked things off with a discussion of AD in pediatric patients, revealing the top questions he receives about eczema and how he advises his patients. He later reviewed the latest approvals in biologics, highlighting dupilumab as the only FDA-approved biologic treatment for AD in infants.
Janus kinase (JAK) pioneer, Dr. King, returned to update attendees on the use of JAK inhibitors for the treatment of AD. Dr. Bunick then took attendees through some of the adverse effects of AD, examining certain risk factors and safety issues that have been reviewed over the years. Dr. Lio concluded this two-and-a-half-hour session with a discussion on comorbidities associated with AD and how these affect the quality of life. The all-star panel then took questions from the audience.
As we close SBS this Sunday, Feb. 12, we know you are eager to get back and put all you have learned into practice.
We would like to extend our thank you to all attendees, sponsors, and faculty for joining us. We hope you had a wonderful time and look forward to seeing you for SBS 2024 next Feb. 8-11, right here in Miami Beach!